Please login to the form below

Not currently logged in
Email:
Password:

Bispecific antibodies

This page shows the latest Bispecific antibodies news and features for those working in and with pharma, biotech and healthcare.

Merus makes case for bispecific antibody in specific cancer gene fusion

Merus makes case for bispecific antibody in specific cancer gene fusion

Could become a potential treatment for hard-to-treat cancers. Merus, a Dutch biotech developing full-length bispecific antibodies, has presented early clinical data of its lead candidate in cancers with

Latest news

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    It hopes to break into the big league with the launch of its own proprietary product by 2025 in addition to a string of collaborations based on its novel antibodies. ... In addition to traditional antibodies, the pipeline also includes antibody drug

  • Deal Watch December 2016 Deal Watch December 2016

    511. BioInvent (Sweden). Pfizer (US). Research collaboration. Development of immuno-regulatory antibodies targeting tumour-associated myeloid cells. ... Technology. Merus. Incyte. $3, 000m. $120m plus $80m equity. Bispecific antibodies.

  • Deal Watch September 2016 Deal Watch September 2016

    In return, Zymeworks is licensing immuno-oncology antibodies from Daiichi Sankyo, in exchange for royalties on sales. ... 624. EngMab / Celgene. Acquisition corporate. T cell bispecific antibodies that bind simultaneously to a tumour antigen and the T

  • Deal Watch June 2016 Deal Watch June 2016

    2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell malignancies (preclinical) and other rights. ... licence. 125. EpimAb Biotherapeutics/ Innovent Biologics. Fabs-In-Tandem immunoglobulin platform to develop multiple

  • Deal Watch April 2016 Deal Watch April 2016

    The collaboration provides GSK with a platform technology to develop bispecific antibodies. ... 125 . Enumeral (US). Pieris (DE). License &option to further programme. Discovery state 388D4 programme of PD1 Monoclonal Antibodies immunotherapies.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... pipeline. As we saw at the recent ASCO meeting, bispecific antibodies are leading a paradigm shift in cancer care and the

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics